drugset / Trial / NCT02215772

Metabolism and Pharmacokinetics of [14C]-BI 44370 BS Administered as an Oral Solution in Healthy Male Volunteers

NCT02215772

Phase 1 Completed 8 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

Study to investigate the basic pharmacokinetics of BI 44370 BS, its metabolite CD 10419 BS, and 14C-radioactivity including mass balance, excretion pathways, and metabolism following a single oral administration of 200 mg \[14C\]BI 44370 BS to healthy male volunteers and to evaluate safety and tolerability following a single oral administration of 200 mg \[14C\]BI 44370 BS to healthy male volunteers

Timeline

Start
2008-09
Primary completion
2008-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 44370 Small molecule 2.43 mbq Oral
Subject BI 44370 Small molecule 200 mg Oral

Indications

No indication recorded.